The FDA has expanded its approval of Skyrizi to include subcutaneous induction for adults with moderately to severely active Crohn’s disease.
Risankizumab (Skyrizi, AbbVie) was approved in 2022 for this patient population as an IV induction regimen followed by subcutaneous maintenance.
The latest approval allows patients to start treatment from home with an on-body injector induction pack, according to a manufacturer release.
Data from the phase 3 AFFIRM trial supported the approval, the release noted. Results showed nearly twice as many patients who received the subcutaneous induction regimen

New guidance from ACOG addresses the use of GLP-1 receptor agonists around pregnancy and lactation, when safety data remain limited.
ACOG called the guidance “long-awaited” as GLP-1 use increases among people of reproductive age.
“Currently, as many as one in 300 women are exposed to GLP-1s prior to pregnancy,” lead guideline author D. Yvette LaCoursiere, MD, FACOG, said in a press release. “In addition to getting prescriptions from their clinicians, these medications are now widely accessible through online providers and medical spas. This means the likelihood of exposure in pregnancy is

WASHINGTON — The public’s trust in the CDC and HHS to provide health information remains low, but trust in personal healthcare providers has increased, according to survey data presented at IDWeek.
“We ran this study because we knew that trust in CDC and other health organizations has been declining since the COVID-19 pandemic,” Hannah Melchinger, MPH, research coordinator at the University of Texas Southwestern Medical Center, told Healio.
Melchinger added that she and her colleagues have been tracking trust in the CDC and similar organizations — as reported by U.S. adults — through surveys

NASHVILLE, Tenn. — Patients with ileal Crohn’s disease had significantly better clinical and endoscopic outcomes at week 54 with subcutaneous vs. IV infliximab therapy, according to a presenter at ACG Annual Scientific Meeting.
“Across every single endpoint, [subcutaneous maintenance] was better than IV maintenance for patients,” Marla C. Dubinsky, MD, codirector of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Icahn School of Medicine, told attendees.
Dubinsky emphasized the difficulties clinicians face when treating the ileal CD phenotype. Although surgical

The FDA has approved once-weekly insulin icodec-abae 700 U/mL for children aged 10 years and older with type 2 diabetes, Novo Nordisk announced.
As Healio previously reported, insulin icodec-abae (Awiqli, Novo) was approved by the FDA in March as the first once-weekly basal insulin for adults with type 2 diabetes. The new indication from the FDA makes insulin icodec-abae the first once-weekly basal insulin available for children. The therapy was approved as an adjunct to diet and exercise to improve glycemic control.
According to the press release, the FDA expanded insulin icodec-abae’s

ANAHEIM, Calif. — Children wearing Acuvue Abiliti 1-Day lenses had significantly lower myopia progression across 3 years of wear compared with a control group, according to data presented at Academy 2026.
“Simultaneous vision soft contact lenses control myopia progression through introducing myopic defocus into the eye. ... Such designs inevitably will degrade vision to various degrees, which limits the amount of plus power that can be introduced to the lens in order to optimize the lens’ myopia control efficacy,” Xu Cheng, MD, PhD, MBA, director, clinical science, at Johnson & Johnson,

WASHINGTON — Approximately 1 in 7 people living in states with a high incidence of Lyme disease will contract the tickborne illness by the time they reach their early 80s, according to a modeling study.
Researcher Riyadh H. Baksh, MS, who presented the study at IDWeek, said the goal was to calculate the “cumulative probability” of a person receiving at least one Lyme disease diagnosis at some point in their life.
“Our objective was to do exactly that — estimate the lifetime risk of Lyme disease,” Baksh, a PhD student in epidemiology at Brown University and part-time researcher at Pfizer, said

DENVER — Socioeconomic, demographic, clinical and genetic factors may impact odds of becoming a living kidney donor, according to study data presented at ASN Kidney Week.
Understanding how living kidney donor candidates move through the evaluation process is an important but underexplored focus of research, according to Krista Lentine, MD, PhD, medical director of living donation at the SSM Health Saint Louis University Hospital Transplant Center, and colleagues. Thus, the researchers used data from the Scientific Registry of Transplant Recipients (SRTR) Living Donor Collective pilot registry

The addition of a personalized vaccine to standard adjuvant therapy reduced risk for recurrence or death by 42% among patients with completely resected high-risk melanoma, according to results of the randomized phase 3 INTerpath-001 trial.
The combination also reduced risk for distant metastasis or death by 38%, findings scheduled for presentation during ESMO Congress showed.
“The transformative INTerpath-001 results have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma in the adjuvant setting,” Georgina Long AO, BSc (Hons1, UM) PhD, MBBS (Hons),

DENVER — Pregnancy after kidney donation was associated with a 50% increased risk for some pregnancy-related adverse outcomes, but the actual number of events was “modest,” according to a speaker.
“The main message is that most pregnancies after living kidney donation were uncomplicated,” Amit X. Garg, MD, PhD, told Healio.
Garg presented data at ASN Kidney Week, and the study was published simultaneously in JAMA.
Garg and colleagues used data from linked healthcare administrative databases on residents of Ontario, British Columbia and Alberta, Canada, using the country’s free universal